

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

053665-5012

APPLICATION NO

10/781,894

APPLICANT

Louis S. KUCERA et al.

FILING DATE

February 20, 2004

GROUP

To Be Assigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JDA/	A01	4,221,732	09/09/1980	Oette et al.	260	403	
	A02	4,291,024	09/22/1981	Turcotte	424	180	
	A03	4,559,157	12/17/1985	Smith et al.	252	90	
	A04	4,608,392	8/26/86	Jacquet et al.	514	844	
	A05	4,622,392	11/11/1986	Hong et al.	536	29	
	A06	4,724,232	02/09/1988	Rideout et al.	514	50	
	A07	4,797,479	01/10/1989	Shuto et al.	536	27	
	A08	4,820,508	04/11/1989	Wortzman	424	59	
	A09	4,921,951	05/01/1990	Shuto et al.	536	27	
	A10	4,938,949	07/03/90	Borch et al.	242	10	
	A11	4,992,478	02/12/1991	Geria	514	782	
	A12	4,997,761	03/05/1991	Jett-Tilton	435	240.2	
	A13	5,221,696	06/22/1993	Ke et al.	514	786	
	A14	5,512,671	04/30/96	Piantadosi	536	26.1	
	A15	5,985,854	11/16/1999	Kozak	514	75	
	A16	6,030,960	02/29/2000	Morris-Natschke et al.	514	77	
	A17	6,077,837	6/20/2000	Kozak	514	77	
	A18	6,136,796	10/24/2000	Kozak	514	75	
	A19	6,166,089	12/26/2000	Kozak	514	642	
↓	A20	6,243,759	4/30/1999	Kucera et al.	709	238	
/JDA/	A21	6,670,341	12/30/03	Kucera, et al.	514	77	

EXAMINER

/James Anderson/

DATE CONSIDERED

01/09/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

053665-5012

APPLICATION NO

10/781,894

APPLICANT

Louis S. KUCERA et al.

FILING DATE

February 20, 2004

GROUP

To Be Assigned

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/JDA/	B01	0 350 287	01/10/1990	EPO				
	B02	0 533 825	4/24/1996	EPO (English)				
	B03	2 239 243 A	06/26/1991	Great Britain				
	B04	42-13841	08/05/1967	Japan				
	B05	61-238793	10/24/1986	Japan				
	B06	10-293129	11/4/1989	Japan				
	B07	90/00555	01/25/1990	WIPO				
	B08	91/19726	12/26/1991	WIPO				
	B09	93/00910	01/21/1993	WIPO				
	B10	94/28908	12/22/1994	WIPO				
	B11	98/17679	4/30/1998	WIPO (English)				
/JDA/	B12	01/19320	3/22/2001	WIPO				

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

/JDA/	C01	Amari, J. V. et al., "Isolation of Experimental Anti-AIDS Glycerophospholipids by Micro-Preparative Reversed-Phase High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> , 590, 153-161, 1992
	C02	Bartlett, J. G., "Antiretroviral Therapy in Patients with HIV Infection", <u>Infectious Diseases in Clinical Practice</u> , 5:172-179, 1996
	C03	Berdel, W. E. et al., "Cytotoxicity of Thioether-Lysophospholipids in Leukemias and Tumors of Human Origin," <u>Cancer Research</u> , Vol. 43, 5538-5543, 1983.
	C04	Braekman, R. et al., "Pharmacokinetics (PK) of Depocyt™ after Intrathecal Administration for the Treatment of Leptomeningeal Metastases (LM)", <u>Proc. Amer. Soc. for Clinical Oncology</u> , Abstract # 810, 1997.
	C05	Caliendo, A. M. et al., "Combination Therapy for Infection Due to Human Immunodeficiency Virus Type 1", <u>Clinical Infectious Diseases</u> , Vol. 18, pp. 516-24, 1994
	C06	Capizzi, R. L., "Curative Chemotherapy for Acute Myeloid Leukemia: the Development of High-Dose Ara-C from the Laboratory to Bedside", <u>Investigational New Drugs</u> 14: 249-256, 1996
/JDA/	C07	Chen, X. et al., "Design and Synthesis of Novel Nucleoside Analogs as Potential Antiviral Agents," Abstract <u>American Assoc. of Pharmaceutical Scientists</u> , Vol. 9, No. 10, 1992

EXAMINER

/James Anderson/

DATE CONSIDERED

01/09/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5012	10/781,894
	APPLICANT	
	Louis S. KUCERA et al.	
	FILING DATE	GROUP
	February 20, 2004	To Be Assigned

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

/JDA/	C08	Coe, D. M. et al., "Preparation of Nucleotide Mimics with Potent Inhibitory Activity Against HIV Reverse Transcriptase," <u>J. Chem. Soc. Perkin Trans 1</u> , 3378-3379, 1991.
	C09	Dal Pan, G. et al., "Preliminary Analysis of the GLIADEL® Treatment Protocol", <u>Proc. Amer. Soc. for Clinical Oncology</u> , Abstract # 1384, 1997
	C10	Daniel, L. W. et al., "Characterization of Cells Sensitive and Resistant to ET-18-OCH <sub>3</sub> ", <u>Abstract 2447, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416, March 1990
	C11	De Clercq, E., "Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections", <u>Journal of Medicinal Chemistry</u> , Vol. 38, No. 14, pp. 2491-2517, 1995
	C12	Eron, J. J. et al., "Resistance of HIV-1 to Antiretroviral Agents in Blood and Seminal Plasma: Implications for Transmission", <u>AIDS 12</u> : F181-F189, 1998
	C13	Fauci, A. S., "Host Factors and the Pathogenesis of HIV-Induced Disease", <u>Nature</u> , 384: 529-534, 1996
	C14	Fujiwara K., et al., "Comparison of Cell Kill Induced by Two Ether Lipids in Combination with Hyperthermia," <u>Proceedings of the American Association for Cancer Research; Preclinical Pharmacology Experimental Therapeutics</u> , Vol. 31, pp. 416, Abstract 2467, March 1990
	C15	Gill, P. S. et al., "Azidothymidine Associated with Bone Marrow Failure in the Acquired Immunodeficiency Syndrome (AIDS)", <u>Annals of Internal Medicine</u> 107: 502-505, 1987
	C16	Goodman and Gilman, <u>The Pharmacological Basis of Therapeutics</u> , Ninth Ed., 1996
	C17	Gordeev, K. et al., "Synthesis of Thio Analogs of Platelet Activating Factor (PAF)," <u>Bioorg. Khim.</u> , Vol. 12, No. 7, pages 951-955, 1986
	C18	Hancock, J. et al., "Analogues of Natural Lipids. VII. Synthesis of Cyclopentanoid Analogs of Phosphatidylcholine," <u>Journal of Lipid Research</u> , Vol. 23, 183-189, 1982
	C19	Hayashi, M et al., "Antitumor Activity of a Novel Nucleotide Derivative, 5'-(1,2 Dipalmitoyl-sn-glycero-3-phospho)-5-fluorouridine (TJ14026) on Murine Tumors," <u>Biol. Pharm. Bull.</u> , 16(8), 778-81, 1993
	C20	Hendrickson, H. S. et al., "A Facile Asymmetric Synthesis of Glycerol Phospholipids via Triylglycidol Prepared by the Asymmetric Epoxidation of Allyl Alcohol, Thioester and Thioether Analogs of Phosphatidylcholine", <u>Chemistry and Physics Lipids</u> , Vol. 53, No. 1, pages 115-120, 1990
	C21	Hong, C. I. et al., "Nucleoside Conjugates. 11. Synthesis and Antitumor Activity of 1-β-D-Arabinofuranosylcytosine and Cytidine Conjugates of Thioether Lipids", <u>Journal of Medicinal Chemistry</u> 33: 1380-1386, 1990
	C22	Hong, C. et al., "Formulation, Stability and Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Conjugate of Thioether Phospholipid", <u>Cancer Res.</u> 50: 4401-4406, 1990
	C23	Hong, C. I. et al., "Nucleoside Conjugates. 15. Synthesis and Biological Activity of Anti-HIV Nucleoside Conjugates of Ether and Thioether Phospholipids," <u>J. Med. Chem.</u> , Vol. 39, No. 9, pages 1771-1777, 1996
	C24	Hong, C.I. et al., "Nucleoside-Ether Lipid Conjugates as Biotransformed Prodrugs of Antitumor and Antiviral Nucleosides," <u>J. Lipid Mediators Cell Signaling</u> , Vol., 10, No. 1-2, pages 159-161, 1994
✓	C25	Hostetler, K. et al., "Antiviral Activity of Phosphatidyl-Dideoxycytidine in Hepatitis B-infected Cells and Enhanced Hepatic Uptake in Mice," <u>Antiviral Research</u> , 59-65, 1994
/JDA/	C26	Hostetler, K. et al., "Phosphatidylazidothymidine and Phosphatidyl-ddC: Assessment of Uptake in Mouse Lymphoid Tissues and Antiviral Activities in Human Immunodeficiency Virus-Infected Cells and in Rauscher Leukemia Virus-Infected Mice", <u>Antimicrobial Agents and Chemotherapy</u> , Dec. 1994, 2792-2797

EXAMINER	/James Anderson/	DATE CONSIDERED	01/09/2008
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO.	APPLICATION NO
		053665-5012	10/781,894
		APPLICANT	
		Louis S. KUCERA et al.	
		FILING DATE	GROUP
		February 20, 2004	To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
/JDA/	C27	Hostetler, K. et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides," <u>Journal of Biological Chemistry</u> , 265: 6112-6117, 1990	
	C28	Hostetler et al., "Phosphatidylazidothymidine: Mechanism of Antiretroviral Action in CEM Cells," <u>Journal of Biological Chemistry</u> , 266: 11714-11717, 1991	
	C29	Jahne, G. et al., "Preparation of Carbocyclic Phosphonate Nucleosides," <u>Tetrahedron Letters</u> , Vol. 33, No. 37, 5335-5338, 1992	
	C30	Jayasuriya, N. et al., "Design, Synthesis, and Activity of Membrane-Disrupting Bolaphiles," <u>J. Am. Chem. Soc.</u> , 112, 5844-5850, 1990	
	C31	Jia, C. et al., "Diamide Analogues of Phosphatidyl Choline as Potential Anti-AIDS Agents," <u>J. Chem. Soc.</u> , 2521-2523, 1993.	
	C32	Kucera, L. S. et al., "Novel Membrane Interactive Ether Lipids with Anti-Human Immunodeficiency Virus Activity", <u>Membrane Interactions of HIV</u> , pp. 329-350, 1992	
	C33	Larder, B. A. et al., "HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy", <u>Science</u> 243: 1731-1734, 1989	
	C34	Lister, M. D. et al., "Cyclopentanoid Analogs of Phosphatidylcholine: Susceptibility to Phospholipase A <sub>2</sub> ," <u>Journal of Lipid Research</u> , Vol. 29, 1297-1308, 1988	
	C35	MacCoss, M. et al., "Synthesis and Biological Activity of Novel Nucleoside-Phospholipid Prodrugs," <u>4th International Round Table Nucleosides, Nucleotides and their Biological Applications</u> , Antwerp, p. 255-263, February 4-6, 1981	
	C36	Mertes, M. P. et al., "Charge-Spatial Models. <i>cis</i> - and <i>trans</i> -3- and -4- Substituted Cyclohexyl Phosphates as Analogs of 2'-Deoxyuridine 5'-Phosphate," <u>Journal of Medicinal Chemistry</u> , Vol. 12(5), 828-832, September 1969	
	C37	Painuly, P. et al., "Preparative HPLC of an Experimental Anti-HIV Analogue of AZT: Azidothymidine Monophosphate Diglyceride (AZT-MP-DG)," <u>Journal of Liquid Chromatography</u> , 16(11), 2237-2248, 1993	
	C38	Pajouhesh, H. et al., "Synthesis of Polar Head Group Homologs of All- <i>trans</i> -cyclopentano-phosphatidylcholine, Phosphatidyl-N, N-Dimethylethanolamine, and Phosphatidylethanolamine," <u>Journal of Lipid Research</u> , Vol. 25, 294-303, 1984	
	C39	Pidgeon, C. et al., "Antiviral Phospholipids Anti-HIV Drugs Conjugated to the Glycerobackbone of Phospholipids," <u>The Journal of Biological Chemistry</u> , 268: 7773-7778, 1993	
	C40	Poiesz, B. J. et al., "Detection and Isolation of Type C Retrovirus Particles From Fresh and Cultured Lymphocytes of a Patient with Cutaneous T-Cell Lymphoma", <u>Proc. Natl Acad. Sci. U.S.A.</u> , 77: 7415-7419, 1980	
	C41	Qiu, X. et al., "Membrane Properties of Antiviral Phospholipids Containing Heteroatoms in the Acyl Chains," <u>Biochemistry</u> , 33(4), 960-72, 1994	
↓	C42	Raetz, C. R. H. et al., "A Phospholipid Derivative of Cytosine Arabinoside and its Conversion to Phosphatidylinositol by Animal Tissue," <u>Science</u> 196, 303-304, 1977	
/JDA/	C43	Richman, D. D. et al., "The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex", <u>New England Journal of Medicine</u> 317: 192-197, 1987	

EXAMINER	DATE CONSIDERED
/James Anderson/	01/09/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO.	APPLICATION NO
		053665-5012	10/781,894
		APPLICANT	
		Louis S. KUCERA et al.	
		FILING DATE	GROUP
		February 20, 2004	To Be Assigned


  

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
/JDA/	C44	Runge, M. H. et al., "Destruction of Human Solid Tumors by Alkyl Lysophospholipids," <u>Journal of the National Cancer Institute</u> , Vol. 64, 1301-1306, 1980
	C45	Sidoti, C. et al., "Cytostatic Activity of New Synthetic Anti-Tumor AZA-Alkyllysophospholipids," <u>Int. J. Cancer</u> 51, 712-717, 1992
	C46	Steim, J. M. et al., "Lipid Conjugates of Antiretroviral Agents. I. Azidothymidine-Monophosphate-Diglyceride: Anti-HIV Activity, Physical Properties, and Interaction with Plasma Proteins," <u>Biochemical and Biophysical Research Communications</u> , Vol. 171, No. 1, 451-457, 1990
	C47	Sudo, K. et al., "Inhibitory Effects of Podophyllotoxin Derivatives on Herpes Simplex Virus Replication," <u>Antiviral Chemistry and Chemotherapy</u> , 9:186, pp. 263-267, 1998
	C48	Surbone, A. et al., "Treatment of the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex with a Regimen of 3'-Azido-2'3'-Dideoxythymidine (Azidothymidine or Zidovudine) and Acyclovir," <u>Annals of Internal Medicine</u> , 108: 534-540, 1988
↓	C49	Tarnowski, G. S. et al., "Effect of Lysolecithin and Analogs on Mouse Ascites Tumors", <u>Cancer Research</u> , Vol. 38, 339-344, 1978
/JDA/	C50	van Wijk, G. M. T. et al., "Synthesis and Antiviral Activity of 3'-azido-3'-deoxythymidine Triphosphate Distearoylglycerol: A Novel Phospholipid Conjugate of the Anti-HIV Agent AZT," <u>Chemistry and Physics of Lipids</u> , 70, 213-222, 1994
	C51	
	C52	
	C53	
	C54	
	C55	
	C56	
	C57	
	C58	
	C59	
	C60	
	C61	

EXAMINER      /James Anderson/	DATE CONSIDERED      01/09/2008
--------------------------------	---------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)</p> </div> <div style="width: 50%;"> <p>ATTY DOCKET NO. <b>053665-5012-00</b></p> <p>APPLICATION NO. <b>10/781,894</b></p> <p>APPLICANT <b>Louis S. KUCERA et al.</b></p> <p>FILING DATE <b>February 20, 2004</b></p> <p>GROUP <b>To Be Assigned</b></p> </div> </div>							
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	A01	2,086,585	Taub et al.	260	127		
	A02	2,087,132	Taub et al.	260	127		
	A03	2,108,765	Domagk	167	30		
	A04	2,209,383	Bock	8	116		
	A05	2,439,969	Fourneau	260	338		
	A06	2,445,393	Fourneau	260	338		
	A07	2,513,747	Sallman et al.	260	338		
	A08	2,606,909	Blicke	260	338		
	A09	2,689,790	Mowry et al.	71	2.7		
	A10	2,950,253	Kling et al.	252	152		
	A11	3,054,678	Michener et al.	99	150		
	A12	3,694,473	Eibl et al.	260	403		
	A13	4,093,714	Tolman et al.	424	180		
	A14	4,096,278	Queuille	424	329		
	A15	4,119,714	Kny et al.	424	199		
	A16	4,159,988	Eibl et al.	260	340.9R		
	A17	4,235,877	Fullerton	424	89		
	A18	4,329,302	Hanahan et al.	260	925		
	A19	4,426,525	Hozumi et al.	546	22		
	A20	4,444,766	Bosies et al.	424	211		
	A21	4,471,113	MacCoss	536	29		
	A22	4,540,521	Garst et al.	260	459		
EXAMINER			DATE CONSIDERED				
/James Anderson/			01/09/2008				
<p><small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small></p>							

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY DOCKET NO. 053665-5012-00	APPLICATION NO 10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE. February 20, 2004	GROUP To Be Assigned

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JDA/	A23	4,619,917	10/28/1986	Lee et al.	514	77	
	A24	4,661,509	04/28/1987	Gordon et al.	514	397	
	A25	4,816,450	03/28/1989	Bell et al.	514	25	
	A26	4,826,823	05/02/1989	Cook et al.	514	46	
	A27	4,835,263	05/30/1989	Nguyen et al.	536	27	
	A28	4,837,023	06/06/1989	Eibl	424	439	
	A29	4,841,039	06/20/1989	Chu et al.	536	29	
	A30	4,880,782	11/14/1989	Eckstein et al.	514	45	
	A31	5,026,687	6/25/1991	Yarchoan et al.	514	45	
	A32	5,034,394	07/23/1991	Daluge	514	261	
	A33	5,138,045	08/11/1992	Cook et al.	536	27	
	A34	5,496,546	03/05/1996	Wang et al.	424	78.36	
	A35	5,614,548	03/25/1997	Piantadosi et al.	514	440	
	A36	5,633,388	05/27/1997	Diana et al.	548	305.7	
	A37	5,770,584	06/23/1998	Kucera et al.	514	77	
	A38	5,830,905	11/03/1998	Diana et al.	514	322	
	A39	5,846,964	12/08/1998	Ozeki	514	182	
	A40	5,891,874	04/06/1999	Colacino et al.	514	234.5	
	A41	5,922,757	07/13/1999	Chojkier	514	458	
	A42	5,962,437	10/05/1999	Kucera et al.	514	77	
/JDA/	A43	6,034,134	03/07/2000	Gold et al.	514	579	

EXAMINER      /James Anderson/	DATE CONSIDERED      01/09/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)				ATTY DOCKET NO. <b>053665-5012-00</b>		APPLICATION NO <b>10/781,894</b>			
				APPLICANT <b>Louis S. KUCERA et al.</b>					
				FILING DATE <b>February 20, 2004</b>		GROUP <b>To Be Assigned</b>			
<b>FOREIGN PATENT DOCUMENTS</b>									
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
/JDA/	B01	0 094 586	11/23/1983	EPO (English)					
/JDA/	B02	0 109 255	05/23/1984	EPO (English)					
/JDA/	B03	0 142 333	05/22/1985	EPO (English)					
/JDA/	B04	0 145 303	06/19/1985	EPO (English)					
/JDA/	B05	0 146 258	06/26/1985	EPO (English)					
	<del>B06</del>	<del>0 252 310</del>	<del>01/13/1988</del>	<del>EPO</del>	<b>NO TRANSLATION</b>			<b>X</b>	
/JDA/	B07	0 310 109	04/05/1989	EPO (English)					
/JDA/	B08	0 335 396	04/10/1989	EPO (English)					
/JDA/	B09	0 348 859	01/03/1990	EPO (English)					
	B10	0 416 401	03/13/1991	EPO			X Abs		
	B11	0 434 450	06/26/1991	EPO (English)					
	B12	0 506 704	07/11/1991	EPO					
	B13	0 632 048	01/04/1995	EPO (English)					
	B14	1,561,630	03/28/1969	France			X Abs		
	B15	199 14 474	10/07/1999	Germany			X Abs		
	B16	37 26 945 A1	02/23/1989	Germany			X Abs		
	B17	39 34 820 A1	04/25/1991	Germany			X Abs		
	/JDA/	B18	40 10 228 A1	10/02/1991	Germany			X Abs	
	EXAMINER      /James Anderson/				DATE CONSIDERED      01/09/2008				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)				ATTY DOCKET NO. 053665-5012-00		APPLICATION NO 10/781,894		
				APPLICANT Louis S. KUCERA et al.				
				FILING DATE February 20, 2004		GROUP To Be Assigned		
<b>FOREIGN PATENT DOCUMENTS</b>								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/JDA/	B19	1029319	01/31/1989	Japan			X Abs	
	<del>B20</del>	<del>49-100224</del>	<del>09/21/1974</del>	<del>Japan</del>	<b>NO TRANSLATION</b>			<b>X</b>
/JDA/	B21	08-268890	10/15/1996	Japan			X Abs	
	B22	10-101591	04/21/1998	Japan			X Abs	
	B23	90/05736	05/31/1990	WIPO (English)				
	B24	90/15601	12/20/1990	WIPO (English)				
	B25	91/05558	05/02/1991	WIPO			X Abs	
	B26	91/09602	07/11/1991	WIPO			X Abs	
	B27	91/18914	12/12/1991	WIPO (English)				
	B28	92/03462	03/05/1992	WIPO			X Abs	
	B29	92/06192	04/16/1992	WIPO (English)				
	B30	93/08807	05/13/1993	WIPO (English)				
	B31	93/16091	08/19/1993	WIPO			X Abs	
	B32	93/16092	08/19/1993	WIPO			X Abs	
	B33	93/17020	09/02/1993	WIPO (English)				
	B34	93/21191	10/28/1993	WIPO (English)				
	B35	WO 98/22496	5/28/1998	WIPO (English)				
	B36	WO 98/17679	4/30/1998	WIPO (English)				
/JDA/	B37	WO 99/07734	2/18/1999	WIPO (English)				
EXAMINER      /James Anderson/				DATE CONSIDERED      01/09/2008				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO. 053665-5012-00	APPLICATION NO 10/781,894
		APPLICANT Louis S. KUCERA et al.	
		FILING DATE February 20, 2004	GROUP To Be Assigned
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
/JDA/	C01	Aggarwal, S. K. et al., "Synthesis and Biological Evaluation of Prodrugs of Zidovudine", <u>J. Med. Chem.</u> , 33, 1505-10 (1990)	
	C02	Alt M. et al., "Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Potent and Specific Inhibitors of Hepatitis C Viral Translation", <u>Archives of Virology</u> 142:589-599, 1997	
	C03	Alt M. et al., "Specific Inhibition of Hepatitis C Viral Gene Expression by Antisense Phosphorothioate Oligodeoxynucleotides", <u>Hepatology</u> 22:707-717, September 1995	
	C04	Anderson, L. J. et al., "Antigenic Characterization of Respiratory Syncytial Virus Strains with Monoclonal Antibodies", <u>Journal of Infectious Diseases</u> , 151:626-633 (April 1985)	
	C05	Attwood, M. R. et al., "The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3-4A Proteinase", <u>Antiviral Chemistry and Chemotherapy</u> 10:259-273, September 1999	
	C06	Battaglia, A.M. et al., "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection", <u>The Annals of Pharmacotherapy</u> 34:487-494, April 2000	
	C07	Berenguer, M. et al., "Hepatitis C Virus in the Transplant Setting", <u>Antiviral Therapy</u> 3(Suppl. 3):125-136, 1998	
↓	C08	Boldanova, N. B. et al., "Protective Effect of Phosphatidylcholine-Containing Liposomes in Experimental Toxic Hepatitis", <u>Vopr. Med. Khim.</u> , 32, No. 3 (1986) Chemical Abstracts 105, p. 67, Abstract No. 35587k (1986)	
/JDA/	C09	Bosies, E. et al., "Preparation of Lecithin Analogs as Retrovirucides and Virucides", Chemical Abstracts, 115CA; 72142p 1991	
	C10	<del>Chu M. et al., "Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the Fungus <i>Penicillium Griseofulvum</i>", <u>Bioorganic and Medicinal Chemistry Letters</u> 9:1949-1952</del>	
/JDA/	C11	Chu M. et al., "Structure of Sch 68631: A New Hepatitis C Virus Proteinase Inhibitor from <i>Streptomyces</i> sp.", <u>Tetrahedron Letters</u> 37:7229-7232, 1996	
	C12	Cooper, K. E., "The Effectiveness of Ribavirin in the Treatment of RSV", <u>Pediatric Nursing</u> , January-February 2001, 27:95-98	
	C13	Crumpton, S. et al., "Novel Lipid Analogs with Cytostatic and Cytocidal Activity", <u>Anticancer Research</u> , Vol. 8, No. 6, pp. 1361-1366 (Nov.-Dec. 1988)	
	C14	Daniel, L. W. et al., "Alkyl-Linked Diglycerides Inhibit Protein Kinase C Activation by Diacylglycerols", <u>Biochemical &amp; Biophysical Research Communications</u> , 151, 291-97 (Feb. 29, 1988)	
	C15	Dietzfelbinger, "Cytotoxic and Purging Effects of ET-18-OCH3 in Human Malignant Lymphoid Cell Lines in Vitro", Abstract 2472, <u>Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990)	
	C16	Domawchowske J. B. et al., "Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis and Treatment", <u>Clinical Microbiology Reviews</u> , 12:298-309 (April 1999)	
	C17	Englund, J. A., "Prevention Strategies for Respiratory Syncytial Virus: Passive and Active Immunization", <u>J. Pediatr.</u> , August 1999, 135:38-44	
	C18	Falsey A. R. et al., "Acute Respiratory Tract Infection in Daycare Centers for Older Persons", <u>J Am Geriatric Soc.</u> , 1995; 43:30-36	
↓	C19	Falsey A. R. et al., "Viral Respiratory Infections in the Institutionalized Elderly: Clinical and Epidemiologic Findings", <u>J Am Geriatr Soc.</u> , 1992; 40:115-119	
/JDA/	C20	Fields, A. P. et al., "Human Immunodeficiency Virus Induces Phosphorylation of its Cell Surface Receptor", <u>Nature</u> , 333, 278-80 (19 May 1988)	
EXAMINER		/James Anderson/	
DATE CONSIDERED		01/09/2008	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO. 053665-5012-00	APPLICATION NO 10/781,894
		APPLICANT Louis S. KUCERA et al.	
		FILING DATE February 20, 2004	GROUP To Be Assigned
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
/JDA/	C21	Galderisi U. et al., "Antisense Oligonucleotides as Therapeutic Agents", <u>Journal of Cellular Physiology</u> , 181:251-257, 1999	
	C22	Garzon L. S. et al., "Management of Respiratory Syncytial Virus with Lower Respiratory Tract Infection in Infants and Children", <u>AACN Clinical Issues</u> , 2002, 13:421-430	
	C23	Glezen W. P. et al., "Risk of Primary Infection and Reinfection with Respiratory Syncytial Virus", <u>Am J Dis Child</u> , 1986, 140:543-546	
	C24	Graham, F. L. et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5-DNA", <u>Virology</u> , Vol. 52, pp. 456-467, 1973	
	C25	Greenough, <u>Acta. Paediatr. Suppl.</u> , 436:11-14 (2001)	
	C26	Guerguerian, A. et al., "Ribavirin in Ventilated Respiratory Syncytial Virus Bronchiolitis: a Randomized, Placebo-Controlled Trial", <u>Am J Resp Crit Care Med.</u> , 1999, 160:829-834	
	C27	Hacking, D. et al., "Respiratory Syncytial Virus - Virus Biology and the Host Response", <u>Journal of Infection</u> , 2002, 45:18-24	
	C28	Hall C. B. et al., "Infectivity of Respiratory Syncytial Virus by Various Routes of Inoculation", <u>Infect Immun.</u> , 1981, 33:779-783	
	C29	Hall, C. B. et al., "Nosocomial Respiratory Syncytial Virus Infections", <u>N Engl J Med.</u> , 1975, 293:1343-1346	
	C30	Hall C. B. et al., "Respiratory Syncytial Virus Infections in Previously Healthy Working Adults", <u>Clin Infect Dis.</u> , September 15, 2001, 33:792-796	
	C31	Hall C. B. et al., "Respiratory Syncytial Virus Infections Within Families", <u>N Engl J Med</u> , 1976, 294:414-419	
	C32	Hall, C. B., "Respiratory Syncytial Virus and Parainfluenza Virus", <u>N. Engl. J. Med.</u> , 344:1917-1928 (June 21, 2001)	
	C33	Harada, S. et al., "Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay", <u>Science</u> , 229, 563-566 (9 Aug. 1985)	
	C34	Henderson, F. W. et al., "Respiratory-Syncytial-Virus Infections, Reinfections, and Immunity: a Prospective, Longitudinal Study in Young Children", <u>N Engl J Med</u> , 1979, 300:530-534	
	C35	Himmelman, "Studies on the Cross Resistance Pattern of Membrane-Toxic Lipids in Vitro", <u>Abstract 2448, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990)	
	C36	Hirsch, M. S. et al., "Antiviral Agents", <u>Fields Virology</u> , Third edition, Lippincott, Raven Publishers, page 431-466, 1996	
	C37	Hruska, J. F. et al., "In vivo Inhibition of Respiratory Syncytial Virus by Ribavirin", <u>Antimicrob Agents Chemother.</u> , 1982, 21:125-130	
	C38	Hsu, L. et al., "Synthesis of Anti-Restricted Pyrimidine Acyclic Nucleosides", <u>Journal of Organic Chemistry</u> , Vol. 57, No. 12, pp. 3354-3358, (1992)	
	C39	IMPACT RSV Study Group, "Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-Risk Infants", <u>Pediatrics</u> , 1998, 102:531-537	
	C40	<del>Kakiuchi N. et al., "Non-peptide Inhibitors of HCV Serine Proteinase", <u>J. FEBS Letters</u> 421:217-220</del>	
/JDA/	C41	Kasnar, B. et al., "Synthesis of 2',3'-Dideoxy- and 3'-Azido-2',3'-Dideoxy-Pyridazine Nucleosides as Potential Antiviral Agents", <u>Nucleosides &amp; Nucleotides</u> , 13(1-3), pp. 459-479, (1994)	
EXAMINER		/James Anderson/	DATE CONSIDERED 01/09/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5012-00	10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE February 20, 2004	GROUP To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
/JDA/	C42	Kawana, F. et al., "Inhibitory Effects of Antiviral Compounds on Respiratory Syncytial Virus Replication In Vitro", <u>Antimicrob Agents Chemother.</u> , August 31, 1987, (8):1225-30
	C43	Kimpen et al., <u>Respiratory Research</u> , Vol. 3, Suppl. 1, pp. S40-45 (2002)
	C44	Korba, B. E. et al., "Use of a Standardized Cell Culture Assay to Assess Activities of Nucleoside Analogs Against Hepatitis B Virus Replication", <u>Antiviral Research</u> , 19, 55-70 (1992)
	C45	Krugner-Higby, L., et al., "Membrane-Interactive Phospholipids Inhibit HIV Type 1-Induced Cell Fusion and Surface gp160/gp120 Binding to Monoclonal Antibody", <u>AIDS Research and Human Retroviruses</u> , Vol. 11, 705-712, (1995)
	C46	Krugner-Higby, L. A. et al., "Novel Membrane Interactive Ether Lipid Analogs Inhibit HIV-1 Glycoprotein Interaction with CD4 <sup>+</sup> Cells", Abstract 321, 32 <sup>nd</sup> Interscience Conf. on Antimicrobial Agents and Chemotherapy, Anaheim, 164, (11-14 Oct. 1992)
	C47	Kucera, L. S., et al., "Activity of Triciribine and Triciribine-5'-Monophosphate Against Human Immunodeficiency Virus Types 1 and 2", <u>Aids Research and Human Retroviruses</u> , Vol. 9, No. 4, pp. 307-314, (1993)
	C48	Kucera, "Effect of Membrane-Active Ether Lipid (EL) Analogues on Human Immunodeficiency Virus Production Measured by Plaque Assay", <u>Annals of the New York Academy of Sciences</u> , 545-548 (26 Dec. 1990)
	C49	Kucera, "Inhibition of HIV-1 Plaque Formation by a Novel Class of Membrane-Active Ether Lipid Analogs" <u>International Conference on AIDS</u> , Abstract No. W.C.O. 21, June 4-9, 1989, p. 528
	C50	Kucera, "Inhibition of Human Immunodeficiency Virus-1 (HIV-1) by Novel Membrane Interactive Ether Lipids", Abstract No. 2470, <u>Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990)
	C51	Kucera, L., et al., "Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Cell Fusion by Synthetic Phospholipid Analogs", <u>Antiviral Research</u> , p. A260 (1985)
	C52	Kucera, "Investigations on Membrane Active Ether Lipid Analogs that Alter Functional Expression of HIV-1 Induces Glycoproteins and Inhibit Pathogenesis", Abstract, <u>Innovations in Therapy of Human Viral Diseases, Symposium</u> , Research Triangle Park, 16, (6-9 Dec. 1992)
	C53	Kucera, L.S. et al., " <u>In Vitro</u> Evaluation and Characterization of Newly Designed Alkylamidophospholipid Analogues as Anti-Human Immunodeficiency Virus Type 1 Agents", <u>Antiviral Chemistry and Chemotherapy</u> , 1998; 9:157-165
	C54	Kucera, L., et al., "Novel Ether Lipid Analogs of Platelet Activating Factor with Anti-Hepatitis B Virus Activity", Abstract, <u>ICAAC Orlando</u> , (1994)
	C55	Kucera, L. et al., "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation", <u>AIDS Research And Human Retroviruses</u> , 6, 491-501, (1990)
↓	C56	Kucera, L. S. et al., "Synthesis and Evaluation of a Novel Synthetic Phosphocholine Lipid-AZT Conjugate that Double-Targets Wild-Type and Drug Resistant Variants of HIV", <u>Nucleosides, Nucleotides and Nucleic Acids</u> , 23:385-399 (2004)
/JDA/	C57	Kumar, R., et al., "Equal Inhibition of HIV Replication by Stereoisomers of Phosphatidyl-Azidothymidine - Lack of Stereospecificity of Lysosomal Phospholipase A <sub>1</sub> ", <u>The Journal of Biological Chemistry</u> , 267, 20288-20292, (1992)

EXAMINER	/James Anderson/	DATE CONSIDERED	01/09/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO. 053665-5012-00	APPLICATION NO 10/781,894
		APPLICANT Louis S. KUCERA et al.	
		FILING DATE February 20, 2004	GROUP To Be Assigned
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
/JDA/	C58	Maccjak, D. J. et al., "Inhibition of Viral Replication by Nuclease Resistant Hammerhead Birozymes Directed Against Hepatitis C virus RNA", <u>Hepatology</u> , 30 Abstract 995, 1999	
	C59	Marasco, Jr., C. J., "The Synthesis and Biological Activity of Novel Alkylglycerol Derivatives as Inhibitors of Protein Kinase C Activity, Neoplastic Cell Growth, and HIV-1 Infectivity", <u>Dissertation for Ph.D., Univ. of No. Carolina, Chapel Hill</u> , 1990	
	C60	Marasco, C. J. et al., "Synthesis and Biological Activity of Novel Quaternary Ammonium Derivatives of Alkylglycerols as Potent Inhibitors of Protein Kinase C", <u>Journal of Medicinal Chemistry</u> , No. 33, pp. 985-992 (March 1990)	
	C61	Marasco et al., "The Synthesis and Biological Testing of Alkyl Glycerols as Potential Inhibitors of Protein Kinase C", <u>American Assoc. of Pharmaceutical Scientists Abstract</u> , Orlando, FL, (1993)	
	C62	Marx, M. H. et al., "Synthesis and Evaluation of Neoplastic Cell Growth Inhibition of 1-N-Alkylamide Analogues of Glycero-3-Phosphocholine", <u>Journal of Medicinal Chemistry</u> , 31, 858-863 (March 28, 1988)	
	C63	Meert, K. L. et al., "Aerosolized Ribavirin in Mechanically Ventilated Children with Respiratory Syncytial Virus Lower Respiratory Tract Disease: a Prospective Double-Blind Randomized Trial", <u>Crit Care Med.</u> , April 1994, 22:566-572	
	C64	Meyer, K. L., et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents", <u>J. Med. Chem.</u> , 34, 1377-1383, (1991)	
	C65	Meyer, "Synthesis and Evaluation of Anti-HIV-1 Ether Lipids", <u>AAPS Meeting, Atlanta Abstract N. MN-510</u> , p. S-41, (22-25 Oct. 1989)	
	C66	Miller, R. H., et al., "Common Evolutionary Origin of Hepatitis B Virus and Retroviruses", <u>Proc. Natl. Acad. Sci. USA</u> , 83, pp. 2531-2535, (April 1986)	
	C67	Mitsuya, H. et al., "Strategies for Antiviral Therapy in AIDS", <u>Nature</u> , 325, 773-78 (26 February 1987)	
	C68	Modest, "Combination Chemotherapy Studies with Antitumor and Antiviral Ether Lipid Analogs", <u>Abstract 2471, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 Abstract 2471 (March 1990)	
	C69	Modest, E., et al., "Comparison of Cell Kill Induced by Two Ether Lipids in Combination with Hyperthermia", <u>Proceedings of the American Association for Cancer Research: Preclinical Pharmacology Experimental Therapeutics</u> , Vol. 31, pp. 416, Abstract 2467, (March 1990)	
	C70	Modest, E. J. et al., "Pharmacological Effects and Anticancer Activity of New Ether Phospholipid Analogs", <u>The Pharmacological Effect of Lipids III: Role of Lipids in Cancer Research</u> , (IN PRESS), pp. 330-337 (1989)	
✓	C71	Molla, A. et al., "Human Serum Attenuates the Activity of Protease Inhibitors Toward Wild-Type and Mutant Human Immunodeficiency Virus", <u>Virology</u> , 1998, 250:255-262	
/JDA/	C72	Morrey, J. D. et al., "Effects of Zidovudine on Friend Virus Complex Infection in Rfv-3 <sup>ts</sup> Genotype-Containing Mice Used as a Model for HIV Infection", <u>Journal of Acquired Immune Deficiency Syndromes</u> , 3, 500-10 (1990)	
EXAMINER		/James Anderson/	DATE CONSIDERED 01/09/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO. 053665-5012-00	APPLICATION NO 10/781,894
		APPLICANT Louis S. KUCERA et al.	
		FILING DATE February 20, 2004	GROUP To Be Assigned
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
/JDA/	C73	Morris-Natschke, S. L. et al., "Synthesis of Phosphocholine and Quaternary Amine Ether Lipids and Evaluation of <i>in Vitro</i> Antineoplastic Activity", <i>J. Med. Chem.</i> , 36:2018-2025 (1993)	
	C74	Morris-Natschke, S. et al. "Synthesis of Sulfur Analogues of Alkyl Lysophosphospholipid and Neoplastic Cell Growth Inhibitory Properties", <i>J. of Med. Chem.</i> , 29, 2114-17 (1986)	
	C75	Mutson, M. A. et al., "Two Distinct Subtypes of Human Respiratory Syncytial Virus", <i>The Journal of General Virology</i> , 66:2111-2124 (October 1985)	
	C76	Nara, P. L. et al., "Simple, Rapid, Quantitative, Syncytium-Forming Microassay for the Detection of Human Immunodeficiency Virus Neutralizing Antibody", <i>AIDS Research and Human Retroviruses</i> , 3, 283-302 (1987)	
	C77	Nosedá, A. et al., "In Vitro Antiproliferative Activity of Combinations of Ether Lipid Analogues and DNA-interactive Agents Against Human Tumor Cells", <i>Cancer Research</i> , 48, 1788-1791 (April 1, 1988)	
	C78	Nosedá, A. et al., "Neoplastic Cell Inhibition with New Ether Lipids Analogs", <i>Lipids</i> , 22, 878-883 (Nov. 1987)	
	C79	Ostertag, W. et al., "Induction of Endogenous Virus and of Thymidine Kinase by Bromodeoxyuridine in Cell Cultures Transformed by Friend Virus", <i>Proc. Nat. Acad. Sci. USA</i> , 71, 4980-85 (Dec. 1974)	
	C80	Ouyang H., et al., "Structure-Activity Relationship for Enhancement of Paracellular Permeability Across Caco-2 Cell Monolayers by 3-Alkylamido-2-alkoxypropylphosphocholines", <i>J. Med. Chem.</i> , 45:2857-2866 (2002)	
	C81	Pacheco, D. Y. et al., "Mechanisms of Toxicity of Hepsulfam in Human Tumor Cell Lines", Abstract 2446, <i>Proceedings of the American Association for Cancer Research</i> , 81, 412 (May 1990)	
	C82	Piantadosi, C. et al., "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity", <i>J. Med. Chem.</i> , 34, 1408-14 (1991)	
	C83	Pidgeon C. et al., "Novel Acylated Phospholipid Drugs for AIDS", <i>Chemical Abstract</i> , 120:69591, (1994)	
	C84	Piedimonte, G., "The Association Between Respiratory Syncytial Virus Infection and Reactive Airway Disease", <i>Respiratory Medicine</i> , 2002, 96 (Suppl B), S25-S29	
	C85	The PREVENT Study Group, "Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis", <i>Pediatrics</i> , 1997, 99:93-99	
	C86	Prince, G. A., "The Pathogenesis of Respiratory Syncytial Virus Infection in Cotton Rats", <i>Am J Pathol.</i> , 1978, 93:771-91	
	C87	Qasim M.A. et al. "Interscaffolding Additivity. Association of P <sub>1</sub> Variants of Eglin c and of Turkey Ovomucoid Third Domain with Serine Proteinases", <i>Biochemistry</i> 36:1598-1607, 1997	
	C88	Rodriguez, W. J. et al., "Prospective Follow-Up and Pulmonary Functions from a Placebo-Controlled Randomized Trial of Ribavirin Therapy in Respiratory Syncytial Virus Bronchiolitis", <i>Arch Pediatr Adolesc Med</i> , May 1999, 153:469-474	
✓	C89	Sable, C. A. et al., "Orthomyxoviral and Paramyxoviral Infections in Transplant Patients", <i>Infect Dis Clin North Am</i> , December 1995, 9:987-1003	
/JDA/	C90	Sarin, P. S. et al., "Effects of a Novel Compound (AL 721) on HTLV-III Infectivity in Vitro", <i>The New England Journal of Medicine</i> , Vol. 313, 1289-90 (Nov. 14, 1985),	
EXAMINER		/James Anderson/	
DATE CONSIDERED		01/09/2008	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO.	APPLICATION NO
		053665-5012-00	10/781,894
		APPLICANT	
		Louis S. KUCERA et al.	
		FILING DATE	GROUP
		February 20, 2004	To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)			
/JDA/	C91	Scolaro M. J. et al., "Inhibition of Virus Replication with Oligonucleotides", <u>Chemical Abstracts</u> , 117:124476, (1992)	
↓	C92	Siquers, N. et al., "Respiratory Syncytial Virus Bronchiolitis in Infancy is an Important Risk Factor for Asthma and Allergy at Age 7", <u>American Journal of Respiratory and Critical Care Medicine</u> , 161:1501-1507 (May 2000)	
↓	C93	Small, "Characterization of Cells Sensitive and Resistant to ET-18-OCH <sub>3</sub> ", <u>Abstract 2447, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990)	
↓	C94	Smith, D. W. et al., "A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection", <u>New England Journal of Medicine</u> , July 1991, 325:24-29	
↓	C95	Staat, M.A., "Respiratory Syncytial Virus Infections in Children", <u>Seminars in Respiratory Infections</u> , March 2002, 17:15-20	
↓	C96	Sudo K. et al, <u>Antiviral Chemistry and Chemotherapy</u> 9:186, 1998	
↓	C97	Sudo K. et al., "Establishment of an In Vitro System for Screening Hepatitis C Virus Protease Inhibitors Using High Performance Liquid Chromatography", <u>Antiviral Research</u> 32:9-18, 1996	
/JDA/	C98	Sunamoto, J. et al., "Induction of Cytotoxic T Cell", <u>Chemical Abstracts</u> , 117:68365, (1992)	
↓	C99	<del>Surles, J. R. et al., "Multigram Synthesis of 1-Alkylamido Phospholipids", <u>Lipids</u>, 28, 55-57</del>	
/JDA/	C100	Swayze, E. E., et al., "Synthesis of 1-(2-Aminopropyl) Benzimidazoles, Structurally Related to the Tibo Derivative R82150, With Activity Against Human Immunodeficiency Virus", <u>Bioorganic &amp; Medical Chemistry Letters</u> , Vol. 3, No. 4, pp 543-546, (1993)	
↓	C101	Takeshita N. et al., "An Enzyme-Linked Immunosorbent Assay for Detecting Proteolytic Activity of Hepatitis C Virus Proteinase", <u>Analytical Biochemistry</u> 247:242-246, May 1, 1997	
↓	C102	Thompson, J., et al., "Phospholipid Analog Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Cell Fusion", <u>Abstracts of the 2nd National Conference on Human Retroviruses</u> , Session 18, (1995)	
↓	C103	Tiollais, P., et al., "Hepatitis B. Virus", <u>Scientific American</u> , 116-123, (April 1991)	
↓	C104	Van Wijk, G. M. et al., "Spontaneous and Protein-Mediated Intermembrance Transfer of the Antiretroviral Liponucleotide 3'-Deoxythymidine Diphosphate Diglyceride", <u>Biochemistry</u> , 31, 5912-5917, (June 30, 1992)	
↓	C105	Vos, G. D. et al., "Treatment of Respiratory Failure Due to Respiratory Syncytial Virus Pneumonia with Natural Surfactant", <u>Pediatr Pulmonol.</u> , December 1996, 22:412-415	
↓	C106	Wang, E. E. et al., "Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Prospective Study of Risk Factors and Outcomes in Patients Hospitalized with Respiratory Syncytial Viral Lower Respiratory Tract Infection", <u>J Pediatr</u> , February 1995, 126:212-219	
↓	C107	Whimbey, E. et al., "Community Respiratory Virus Infections Among Hospitalized Adult Bone Marrow Transplant Recipients", <u>Clin Infect Dis.</u> , May 1996, 22:778-782	
↓	C108	Yamaue, H. et al., "Chemosensitivity Testing with Highly Purified Fresh Human Tumor Cells with the MTT Colorimetric Assay", <u>Eur J Cancer</u> , 1991, 27:1258-1263	
↓	C109	Yanagawa, H. et al. "Spontaneous Formation of Superhelical Strands", <u>Journal of the American Chemical Society</u> , 111, 4567-70 (June 21, 1989)	
/JDA/	C110	Yarchoan, R. et al., "Therapeutic Strategies in the Treatment of AIDS", <u>Annual Reports in Medicinal Chemistry</u> , Vol. 23, 253-263 (1988)	

EXAMINER	DATE CONSIDERED
/James Anderson/	01/09/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.